Crinetics Pharmaceuticals, Inc.CRNXEarnings & Financial Report
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
CRNX Q4 FY2025 Key Financial Metrics
Revenue
$6.2M
Gross Profit
N/A
Operating Profit
$-133.7M
Net Profit
$-122.8M
Gross Margin
N/A
Operating Margin
-2169.6%
Net Margin
-1993.4%
YoY Growth
N/A
EPS
$-1.30
Crinetics Pharmaceuticals, Inc. Q4 FY2025 Financial Summary
Crinetics Pharmaceuticals, Inc. reported revenue of $6.2M for Q4 FY2025, with a net profit of $-122.8M (down 52.4% YoY) (-1993.4% margin).
Key Financial Metrics
| Total Revenue | $6.2M |
|---|---|
| Net Profit | $-122.8M |
| Gross Margin | N/A |
| Operating Margin | -2169.6% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Crinetics Pharmaceuticals, Inc. Q4 FY2025 revenue of $6.2M breaks down across 2 segments, led by Products at $5.4M (88.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $5.4M | 88.0% |
| Other | $741.0K | 12.0% |
Crinetics Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Crinetics Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $6.2M | — | $-122.8M | -1993.4% |
| Q2 FY2025 | $1.0M | +158.4% | $-115.6M | -11216.0% |
| Q4 FY2024 | $0 | — | $-80.6M | N/A |
| Q3 FY2024 | $0 | — | $-76.8M | N/A |
| Q4 FY2023 | $0 | — | $-60.1M | N/A |
| Q2 FY2023 | $988.0K | +125.1% | $-51.0M | -5159.8% |
| Q1 FY2023 | $2.7M | -14.4% | $-46.0M | -1716.9% |
| Q4 FY2022 | $-4.0M | — | $-45.0M | 1117.0% |
Income Statement
| Q4 2022 | Q1 2023 | Q2 2023 | Q4 2023 | Q3 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $-4.0M | $2.7M | $988000 | $0 | $0 | $0 | $1.0M | $6.2M |
| YoY Growth | N/A | -14.4% | 125.1% | N/A | N/A | N/A | 158.4% | N/A |
Balance Sheet
| Q4 2022 | Q1 2023 | Q2 2023 | Q4 2023 | Q3 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $352.2M | $314.0M | $293.3M | $635.4M | $937.4M | $1.43B | $1.29B | $1.13B |
| Liabilities | $35.8M | $33.7M | $39.1M | $96.2M | $104.4M | $109.8M | $118.0M | $134.2M |
| Equity | $316.3M | $280.3M | $254.1M | $539.1M | $833.0M | $1.32B | $1.17B | $992.1M |
Cash Flow
| Q4 2022 | Q1 2023 | Q2 2023 | Q4 2023 | Q3 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-35.2M | $-40.7M | $-45.7M | $-40.8M | $-62.8M | $-64.7M | $-85.9M | $-92.9M |